VISSER, Michael Scott,PAPILLON, Julien,LUZZIO, Michael Joseph
申请号:
PH12017500215
公开号:
PH12017500215A1
申请日:
2017.02.03
申请国别(地区):
PH
年份:
2017
代理人:
摘要:
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.